These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1894148)

  • 21. Smoking, cancer, and Parkinson's disease.
    Golbe LI; Bernholc AA; Duvoisin RC
    Ann Neurol; 1987 May; 21(5):513. PubMed ID: 3592644
    [No Abstract]   [Full Text] [Related]  

  • 22. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
    Morale MC; L'Episcopo F; Tirolo C; Giaquinta G; Caniglia S; Testa N; Arcieri P; Serra PA; Lupo G; Alberghina M; Harada N; Honda S; Panzica GC; Marchetti B
    Brain Res Rev; 2008 Mar; 57(2):431-43. PubMed ID: 18063054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Genetic polymorphisms of cytochrome P450 1A1 and susceptibility of early-onset Parkinson's disease].
    Liu P; Liu Z; Shao M; Chen B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Aug; 18(4):283-5. PubMed ID: 11484167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.
    Barbeau A; Cloutier T; Roy M; Plasse L; Paris S; Poirier J
    Lancet; 1985 Nov; 2(8466):1213-6. PubMed ID: 2866293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Parkinson's disease--the molecular mechanism].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1341-52. PubMed ID: 1972586
    [No Abstract]   [Full Text] [Related]  

  • 27. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Parker WD; Boyson SJ; Parks JK
    Ann Neurol; 1989 Dec; 26(6):719-23. PubMed ID: 2557792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Shoffner JM; Watts RL; Juncos JL; Torroni A; Wallace DC
    Ann Neurol; 1991 Sep; 30(3):332-9. PubMed ID: 1952821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complex I and Parkinson's disease.
    Greenamyre JT; Sherer TB; Betarbet R; Panov AV
    IUBMB Life; 2001; 52(3-5):135-41. PubMed ID: 11798025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Debrisoquine hydroxylase and Parkinson's disease.
    Kondo I; Kanazawa I
    Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
    Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
    Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
    Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
    Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
    [No Abstract]   [Full Text] [Related]  

  • 36. Mitochondrial complex-1 in Parkinson's disease.
    Khan SZ
    Neurol India; 2006 Dec; 54(4):351. PubMed ID: 17114838
    [No Abstract]   [Full Text] [Related]  

  • 37. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson's disease].
    Wang J; Liu Z; Chen B
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):585-7. PubMed ID: 11798822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.
    Singh S; Singh K; Patel S; Patel DK; Singh C; Nath C; Singh MP
    Brain Res; 2008 May; 1207():193-206. PubMed ID: 18374908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease.
    Riedl AG; Watts PM; Brown CT; Jenner P
    Adv Neurol; 1999; 80():271-86. PubMed ID: 10410732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.